Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
VYNE Therapeutics Inc. (VYNE) Debt to Capital Ratio data is not available for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.20M |
|
$-8.61M |
|
-- |
|
$0.20M |
|
$9.40M |
|
$-9.20M |
|
$0.59M |
|
$-8.60M |
|
$-8.60M |
|
$-8.60M |
|
$-8.60M |
|
$-8.61M |
|
$-8.60M |
|
$-9.20M |
|
$-9.52M |
|
42.67M |
|
42.67M |
|
$-0.20 |
|
$-0.20 |
|
| Balance Sheet Financials | |
$54.91M |
|
$0.11M |
|
$1.51M |
|
$56.42M |
|
$12.29M |
|
-- |
|
-- |
|
$12.29M |
|
$44.13M |
|
$44.13M |
|
$44.13M |
|
15.96M |
|
| Cash Flow Statement Financials | |
$-11.46M |
|
$19.83M |
|
$-0.09M |
|
$19.93M |
|
$28.21M |
|
$8.28M |
|
$0.76M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.47 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
-- |
-- |
|
100.00% |
|
-4552.97% |
|
-4552.97% |
|
-- |
|
-4258.91% |
|
-4262.87% |
|
$-11.46M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-19.49% |
|
-19.49% |
|
-15.25% |
|
-19.49% |
|
$2.77 |
|
$-0.27 |
|
$-0.27 |
|